Is Imfinzi Effective for Biliary Tract Cancer? (TOPAZ-1 Trial)
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On January 18, 2022, AstraZeneca announced the results of the TOPAZ-1 Phase 3 clinical trial. The study evaluated the efficacy and safety of Imfinzi (durvalumab), an anti-PD-L1 antibody, in combination with standard chemotherapy as a first-line treatment for patients with unresectable advanced or metastatic biliary tract cancer (BTC).
Study Design: TOPAZ-1 Phase 3 Trial
TOPAZ-1 is an international, multi-center, double-blind, randomized Phase 3 trial. It included 685 patients with unresectable advanced or metastatic BTC (including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer). Patients were randomized into two groups:
- Imfinzi Group: Imfinzi + Standard Chemotherapy (Gemcitabine and Cisplatin) (N=341)
- Placebo Group: Placebo + Standard Chemotherapy (N=344)
The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety.
Key Survival Results
Overall Survival (OS)
- Median OS: 12.8 months for the Imfinzi group vs. 11.5 months for the placebo group.
- The Imfinzi combination reduced the risk of death by 20% (Hazard Ratio [HR] = 0.80).
- 18-Month OS Rate: 35.1% (Imfinzi) vs. 25.6% (Placebo).
- 24-Month OS Rate: 24.9% (Imfinzi) vs. 10.4% (Placebo).
Progression-Free Survival (PFS)
- Median PFS: 7.2 months (Imfinzi) vs. 5.7 months (Placebo).
- The risk of disease progression or death was reduced by 20% in the Imfinzi group.
Objective Response Rate (ORR)
- ORR: 26.7% for the Imfinzi group vs. 18.7% for the placebo group.
Safety Profile
The incidence of Grade 3 or 4 adverse events was similar between the two groups: 62.7% in the Imfinzi group and 64.9% in the placebo group. Discontinuation of treatment due to adverse events occurred in 8.9% of patients in the Imfinzi group and 11.4% in the placebo group.
Conclusion
Dr. Do-Youn Oh from Seoul National University Hospital noted that there had been no significant progress in treating advanced biliary tract cancer for over a decade. The TOPAZ-1 trial demonstrates that Imfinzi plus chemotherapy significantly improves overall survival with a favorable safety profile, establishing this combination as a potential new standard of care for advanced BTC.
Source: AstraZeneca Press Release - TOPAZ-1 Results
#BiliaryTractCancer #Cholangiocarcinoma #Imfinzi #Durvalumab #TOPAZ1 #CancerResearch
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1